Rafael Amado - Mar 23, 2022 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
EVP of R&D and CMO
Signature
Veer Bhavnagri as attorney-in-fact for Rafael Amado
Stock symbol
ALLO
Transactions as of
Mar 23, 2022
Transactions value $
$0
Form type
4
Date filed
3/25/2022, 05:52 PM
Previous filing
Mar 17, 2022
Next filing
May 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +237K +74.15% $0.00 557K Mar 23, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Award $0 +369K $0.00 369K Mar 23, 2022 Common Stock 369K $9.69 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter